Skip to main content

Table 4 Pathological and oncological results in trials using presurgical docetaxel ± hormonal therapy

From: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Therapy

Docetaxel + Hormonal Therapy

Docetaxel – Single Treatment

Author year

Current series

Narita 2012

Kim 2011

Mellado 2009

Sella 2008

Chi 2008

Prayer-Galetti 2007

Hussain 2003

Magi-Galuzzi 2007

Febbo 2005

Dreicer 2004

Patients (n)

30

18

24 RP/Rad

57

22

72

22

21

29

19

29

Docetaxel (D) Regime

3 cycles, q21, (75 mg/m2)

6 weeks, q7, (30 mg/m2)

3 cycles, q7 (3xD +1 week rest) (36 mg/m2)

3 cycles, q7 (3xD +1 week rest) (36 mg/m2)

4 cycles, q21 (70 mg/m2)

3 cycles, q7 (6xD +2 weeks rest) (35 mg/m2)

4 cycles, q21, (70 mg/m2)

6 cycles, q21 (70 mg/m2)

6 weeks, q7, (40 mg/m2)

6 months, q7, (36 mg/m2)

6 weeks, q7, (40 mg/m2)

LHRH Analog

buserelin 9.45 mg (1x3 months)

leuprorelin 11.25 mg (2x3 months)

n.d.

goserelin 10.8 mg (1x3 months)

goserelin 3.6 mg (3x1 month)

buserelin 6.6 mg (3x2 months)

triptorelin 3.75 mg (4–12 months)

n.d.

n.d.

n.d.

n.d.

Antiandrogens

bicaluta-mide 50 mg/d (9 weeks)

bicaluta-mide 81 mg/d (12 weeks)

n.d.

flutamide 750 mg/d (12 weeks)

bicaluta-mide 50 mg/d (12 weeks)

flutamide 750 mg/d // bicaluta-mide 50 mg/d (4 weeks)

n.d.

n.d.

n.d.

n.d.

n.d.

Estramustine

n.d.

1120 mg/d (6 weeks)

420 mg/d for 3d

n.d.

840 mg/d for 5d

n.d.

600 mg/m2 (12 weeks)

840 mg/d for 3d

n.d.

n.d.

n.d.

Therapy-weeks

9

6

12

12

12

24

16-60

18

6

24

6

pCR (%)

0

11.1

0

6

0

3.1

5

0

0

0

0

pMRD (%)

3.33

n.d.

n.d.

6

n.d.

25

31.6*

n.d.

n.d.

n.d.

7.14

iPSA, median, range (ng/ml)

25.8

25.8

22.3

9.7

21.2

10.8

41

16.1

n.d.

n.d.

12

2.1-293

5.1-45.1

0.3-255

0.6-90.8

3.2-71.6

1.6-65.6

n.d.

2.4-175

2.5-43.3

iGl. sc. ≥7 (%)

90

87.4

100

95

n.d.

91

86

96

93

75

94

≥cT3 (%)

93.3

43.8

27

28

64

39

86

25

17.8

16

27

≥pT3 (%)

56.5

38.9

72.7

37

36.4

44

42

70

82.1

62

89

SVI (%)

53.3

11.1

45.5

n.d.

40.9

22

37

60

39.3

50

32

R0 (%)

66.7

100

63.6

64.7

72.7

73

74

70

75

n.d.

96

pN1 (%)

36.7

22.2

n.d.

3.9

18.1

6

21

10

14.3

0

14

FU, median, range (months)

48.6

18

24

35

23.6

42.7

53

13.1

49.5

26.5

23

20-88

1-49

n.d.

23-47

12-55

26-66

30-64

9-18

23-72

4.5-40

1.5-36

Recur. Pts. (%)

55.2

22.2

55

35.1

45.4

30.0

58.0

29.0

57.0

63.2

29.0

  1. Abbreviations: CSOS, cancer specific overall survival; cT3, clinical stage T3 with capsular penetration; pT3, pathological stage T3 with capsular penetration; D, docetaxel; FU, follow up; iGl. sc., initial Gleason score; iPSA, initial prostate-specific antigen; LHRH, luteinizing hormone releasing hormone; n.a., not applicable; n.d., not done; pN1, pathological lymph node involvement; pCR, pathological complete response; pMRD, pathological minimal residual disease with <5% PC in surgical specimens; *, pMRD with <10% PC in surgical specimens; q, treatment interval of 7 or 21 days; R0, negative surgical resection margin; RP, radical prostatectomy; Recur. Pts., patients with recurrent PC; RP/Rad, 12 patients treated with RP and 10 with external beam radiation; SVI, seminal vesicle invasion.